Article Text
Statistics from Altmetric.com
Identifying effective and safe therapies for the management of patients with coronavirus disease 2019 (COVID-19) is crucial in the control of the pandemic. The critical role of immune system dysregulation in the pathophysiology of multisystem organ dysfunction following COVID-19 is well recognised. Several attempts have been made to investigate multiple anti-inflammatory drugs with beneficial effects in the management of COVID-19. Recently, the US Food and Drug Administration issued an emergency use authorisation (EUA) for the use of tocilizumab in combination with corticosteroids in hospitalised patients with COVID-19 aged ≥2 years who require non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation. However, there are uncertainties regarding the time, dose and duration of administration. Some efforts have been made to answer these questions.1 2 …
Footnotes
Contributors All authors have contributed equally to the development of the work.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.